Harvard Bioscience Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harvard Bioscience, Inc. on April 28, 2015, with the earliest event reported on that date. The filing primarily addresses corporate governance changes and references the announcement of financial results for the three months ended March 31, 2015, which were issued via press release on April 30, 2015.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Item 2.02 states that financial results for the quarter ended March 31, 2015, are detailed in a press release furnished as Exhibit 99.1, but the content of that exhibit is not included in the provided text.
Material Changes and Corporate Governance
- Board Departure: Robert Dishman retired and resigned as a member of the Board of Directors on April 28, 2015. The filing notes no disagreement with the Company regarding operations or policies.
- Board Appointment: James Green was appointed as a Class I independent director on April 28, 2015, to fill the vacancy. His term lasts until the 2016 annual meeting or until a successor is elected.
- Compensation Arrangement: Mr. Green will receive non-qualified stock options on May 5, 2015. The grant amount will be the greater of options with a Black-Scholes cash value of $120,000 or options to acquire 25,000 shares. These options have a 10-year term and vest in three equal installments over May 5, 2015, 2016, and 2017.
Guidance, Outlook, and Risks
The filing does not contain specific management commentary, forward-looking guidance, or risk factors within the text provided. It explicitly states that the information in Item 2.02 and the attached exhibits shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q1 2015 financial figures (revenue, net income, cash flow) as they are not present in the 8-K body.
- Verify the stock price on May 5, 2015, to determine the exercise price and share count for James Green's stock option grant.
- Confirm the status of the conference call scheduled for April 30, 2015, for additional management commentary on the financial results.
- Check subsequent filings to ensure James Green's appointment was ratified at the 2016 annual meeting.